Isotretinoin as a promising option in the treatment of facial papules of frontal fibrosing alopecia

Frontal fibrosing alopecia (FFA) is a primary cicatricial alopecia characterized by hairline recession, pruritus, and facial papules (FP). Various therapies are used to stabilize disease activity and induce remission. However, FP of FFA is resistant to treatment in many cases. In this review, we sea...

Full description

Saved in:
Bibliographic Details
Published in:International journal of dermatology 2024-12, Vol.63 (12), p.1685-1690
Main Authors: Beyzaee, Amir Mohammad, Babaei, Mahsa, Ghoreishi, Bahare, Waśkiel‐Burnat, Anna, Rudnicka, Lidia, Starace, Michela, Tosti, Antonella, Patil, Anant, Sinclair, Rodney, Goldust, Mohamad, Rahmatpour Rokni, Ghasem
Format: Article
Language:English
Subjects:
Administration, Oral
Alopecia
Alopecia - drug therapy
Alopecia - pathology
Case reports
cicatricial alopecia
Dermatologic Agents - administration & dosage
Dermatologic Agents - therapeutic use
Facial Dermatoses - drug therapy
Facial Dermatoses - pathology
facial papules
Fibrosis - drug therapy
Forehead
frontal fibrosing alopecia
hair loss
Humans
isotretinoin
Isotretinoin - administration & dosage
Isotretinoin - therapeutic use
lichen planopilaris
lichenoid
Pruritus
Remission
retinoids
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Frontal fibrosing alopecia (FFA) is a primary cicatricial alopecia characterized by hairline recession, pruritus, and facial papules (FP). Various therapies are used to stabilize disease activity and induce remission. However, FP of FFA is resistant to treatment in many cases. In this review, we searched the PubMed and Google Scholar databases to screen the published literature on treatment options for FP in the context of FFA. Overall, 12 studies were included in this review. Available literature suggests a noticeable improvement in resistant‐to‐treatment FP in FFA patients with oral isotretinoin. The available evidence is limited and is derived from retrospective studies and case reports/series. Systemic isotretinoin can be considered a promising therapeutic regimen for treating resistant‐to‐treatment FP of FFA patients. However, more extensive, well‐designed studies are necessary for confirmatory evidence.
ISSN:0011-9059
1365-4632
1365-4632
DOI:10.1111/ijd.17356